210 related articles for article (PubMed ID: 30608394)
1. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
[TBL] [Abstract][Full Text] [Related]
2. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
3. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Weiss G; Cottrell S; Distler J; Schatz P; Kristiansen G; Ittmann M; Haefliger C; Lesche R; Hartmann A; Corman J; Wheeler T
J Urol; 2009 Apr; 181(4):1678-85. PubMed ID: 19233404
[TBL] [Abstract][Full Text] [Related]
5.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
6. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
Dietrich D; Hasinger O; Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Wernert N; Perner S; Freedland SJ; Corman JM; Ittmann MM; Lark AL; Madden JF; Hartmann A; Schatz P; Kristiansen G
J Mol Diagn; 2013 Mar; 15(2):270-9. PubMed ID: 23266319
[TBL] [Abstract][Full Text] [Related]
7. Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation.
Schatz P; Dietrich D; Koenig T; Burger M; Lukas A; Fuhrmann I; Kristiansen G; Stoehr R; Schuster M; Lesche R; Weiss G; Corman J; Hartmann A
J Mol Diagn; 2010 May; 12(3):345-53. PubMed ID: 20304943
[TBL] [Abstract][Full Text] [Related]
8. Prediction efficiency of PITX2 DNA methylation for prostate cancer survival.
Luan ZM; Zhang H; Qu XL
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173224
[TBL] [Abstract][Full Text] [Related]
9. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
10. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.
Litovkin K; Joniau S; Lerut E; Laenen A; Gevaert O; Spahn M; Kneitz B; Isebaert S; Haustermans K; Beullens M; Van Eynde A; Bollen M
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1849-61. PubMed ID: 24938434
[TBL] [Abstract][Full Text] [Related]
11. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
Lin YL; Li YL; Ma JG
Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
Sheng X; Guo Y; Lu Y
Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
[TBL] [Abstract][Full Text] [Related]
16. Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.
Semaan A; Uhl B; Branchi V; Lingohr P; Bootz F; Kristiansen G; Kalff JC; Matthaei H; Pantelis D; Dietrich D
Clin Colorectal Cancer; 2018 Jun; 17(2):e385-e393. PubMed ID: 29580650
[TBL] [Abstract][Full Text] [Related]
17. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
Lin YL; Xie PG; Wang L; Ma JG
Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
Wang L; Xie PG; Lin YL; Ma JG; Li WP
Med Sci Monit; 2014 Aug; 20():1363-8. PubMed ID: 25086586
[TBL] [Abstract][Full Text] [Related]
19. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
20. AIM1 promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy.
Rosenbaum E; Begum S; Brait M; Zahurak M; Maldonado L; Mangold LA; Eisenberger MA; Epstein JI; Partin AW; Sidransky D; Hoque MO
Prostate; 2012 Jul; 72(10):1133-9. PubMed ID: 22127895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]